nach oben

Journal of Inherited Metabolic Disease

Erschienen in:

01.03.2013 | Original Article

Heparan sulfate derived disaccharides in plasma and total urinary excretion of glycosaminoglycans correlate with disease severity in Sanfilippo disease

verfasst von: J. de Ruijter, L. IJlst, W. Kulik, H. van Lenthe, T. Wagemans, N. van Vlies, F. A. Wijburg

Erschienen in: Journal of Inherited Metabolic Disease | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Sanfilippo disease (Mucopolysaccharidosis III) is a neurodegenerative lysosomal disorder characterized by accumulation of the glycosaminoglycan heparan sulfate (HS). MPS III has a large phenotypic variability and early assessment of disease severity is difficult. We investigated the correlation between disease severity and the plasma concentration of HS (pHS, defined by the sum of the heparan sulfate derived disaccharides obtained after enzymatic digestion) and urinary total GAGs level (uGAGs, measured by the dimethylene blue test) in a cross-sectional cohort of 44 MPS III patients.

Methods

Disease severity was established on the basis of the age of complete loss of independent walking and of full loss of speech in all patients. Hazard ratios (HR) were obtained with cox-regression analysis. In order to allow prediction of a severe phenotype based on a cut-off value for pHS, patients were divided in two groups (severely affected and less severely affected) based on predictive mutations or on the age of full loss of speech. Receiver operator characteristics (ROC) were obtained for pHS.

Results

pHS and uGAGs were independently and linearly associated with an increased risk of speech loss with a HR of 1.8 (95 % CI 1.3–2.7) per 500 ng/ml increase of HS in plasma (p = 0.002), and a HR of 2.7 (95 % CI 1.6–4.4) per 10 mg/mmol creatinine increase of uGAGs (p < 0.001). pHS and uGAGS were less strongly associated with loss of walking. The area under the ROC curve for pHS was 0.85, indicating good discrimination.

Conclusion

pHS and uGAGs may be useful biomarkers for prediction of severity in MPS III.

Baehner F, Schmiedeskamp C, Krummenauer F et al (2005) Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 28:1011–1017PubMedCrossRef

Ben Turkia H, Tebib N, Azzouz H et al (2009) Incidence of mucopolysaccharidoses in Tunisia. Tunis Med 87:782–785PubMed

Cengiz N, Baskin E, Anarat R et al (2005) Glycosaminoglycans in childhood urinary tract infections. Pediatr Nephrol 20:937–939PubMedCrossRef

Clarke LA, Hemmelgarn H, Colobong K et al (2012) Longitudinal observations of serum heparin cofactor II-thrombin complex in treated Mucopolysaccharidosis I and II patients. J Inherit Metab Dis 35:355–362PubMedCrossRef

de Jong JG, Wevers RA, Laarakkers C, Poorthuis BJ (1989) Dimethylmethylene blue-based spectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for mucopolysaccharidoses. Clin Chem 35:1472–1477PubMed

de Jong JG, Wevers RA, Liebrand-van SR (1992) Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue. Clin Chem 38:803–807PubMed

de Ruijter J, Valstar MJ, Narajczyk M et al (2012) Genistein in Sanfilippo disease: a randomized controlled crossover trial. Ann Neurol 71:110–120PubMedCrossRef

Delgadillo V, O’Callaghan MM, Artuch R, Montero R, Pineda M (2011) Genistein supplementation in patients affected by Sanfilippo disease. J Inherit Metab Dis 34:1039–1044PubMedCrossRef

Di Natale P, Di Domenico C, Di Napoli D (2010) Serum MIP-1 alpha level: a biomarker for the follow-up of lentiviral therapy in mucopolysaccharidosis IIIB mice. J Inherit Metab Dis 33:159–165PubMedCrossRef

Ellinwood NM, Ausseil J, Desmaris N et al (2011) Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Mol Ther 19:251–259PubMedCrossRef

Erickson RP, Sandman R, Epstein CJ (1975) Lack of relationship between blood and urine levels of glycosaminoglycans and lysomal enzymes. Biochem Med 12:331–339PubMedCrossRef

Fedele AO, Hopwood JJ (2010) Functional analysis of the HGSNAT gene in patients with mucopolysaccharidosis IIIC (Sanfilippo C Syndrome). Hum Mutat 31:E1574–E1586PubMedCrossRef

Feldhammer M, Durand S, Mrazova L et al (2009) Sanfilippo syndrome type C: mutation spectrum in the heparan sulfate acetyl-CoA: alpha-glucosaminide N-acetyltransferase (HGSNAT) gene. Hum Mutat 30:918–925PubMedCrossRef

Glamuzina E, Fettes E, Bainbridge K et al (2011) Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points. J Inherit Metab Dis 34:749–754PubMedCrossRef

Harmatz P, Giugliani R, Schwartz I et al (2006) Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 148:533–539PubMedCrossRef

Hendriksz CJ, Giugliani R, Harmatz P et al (2011) Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP). J Inherit Metab Dis. doi:10.1007/s10545-011-9410-9

Heron B, Mikaeloff Y, Froissart R et al (2011) Incidence and natural history of mucopolysaccharidosis type III in France and comparison with United Kingdom and Greece. Am J Med Genet A 155A:58–68PubMed

Hopwood J (2007) Sanfilippo Syndrome: Clinical genetic diagnosis and therapies. Chapter 26. In J. Barranger, Lysosomal Storage Disorders. Springer, Berlin, 415–432

Kaplan D, Meyer K (1962) The fate of injected mucopolysac-charides. J Clin Invest 41:743–749PubMedCrossRef

Langford-Smith KJ, Mercer J, Petty J et al (2011) Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases. J Inherit Metab Dis 34:499–508PubMedCrossRef

Malinová V, Wegrzyn G, Narajczyk M (2012) The Use of Elevated Doses of Genistein-Rich Soy Extract in the Gene Expression-Targeted Isoflavone Therapy for Sanfilippo Disease Patients. J Inherit Metab Dis 5:21–25

Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281:249–254PubMedCrossRef

Muenzer J, Gucsavas-Calikoglu M, McCandless SE, Schuetz TJ, Kimura A (2007) A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab 90:329–337PubMedCrossRef

Muschol N, Pohl S, Meyer A, Gal A, Ullrich K, Braulke T (2011) Residual activity and proteasomal degradation of p.Ser298Pro sulfamidase identified in patients with a mild clinical phenotype of Sanfilippo A syndrome. Am J Med Genet A 155A:1634–1639PubMed

Narajczyk M, Tylki-Szymanska A, Wegrzyn G (2012) Changes in hair morphology as a biomarker in gene expression-targeted isoflavone therapy for Sanfilippo disease. Gene 504:292–295PubMedCrossRef

Ohmi K, Kudo LC, Ryazantsev S, Zhao HZ, Karsten SL, Neufeld EF (2009) Sanfilippo syndrome type B, a lysosomal storage disease, is also a tauopathy. Proc Natl Acad Sci U S A 106:8332–8337PubMedCrossRef

Perkins KJ, Muller V, Weber B, Hopwood JJ (2001) Prediction of Sanfilippo phenotype severity from immunoquantification of heparan-N-sulfamidase in cultured fibroblasts from mucopolysaccharidosis type IIIA patients. Mol Genet Metab 73:306–312PubMedCrossRef

Pinto R, Caseiro C, Lemos M et al (2004) Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet 12:87–92PubMedCrossRef

Piotrowska E, Jakobkiewicz-Banecka J, Tylki-Szymanska A et al (2008) Genistin-rich soy isoflavone extract in substrate reduction therapy for sanfilippo syndrome: an open-label, pilot study in 10 pediatric patients. Curr Ther Res Clin Exp 69:166–179CrossRef

Poorthuis BJ, Wevers RA, Kleijer WJ et al (1999) The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 105:151–156PubMed

Poupetova H, Ledvinova J, Berna L, Dvorakova L, Kozich V, Elleder M (2010) The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations. J Inherit Metab Dis 33:387–396PubMedCrossRef

Ruijter GJ, Valstar MJ, van de Kamp JM et al (2008) Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands. Mol Genet Metab 93:104–111PubMedCrossRef

Valstar MJ, Bertoli-Avella AM, Wessels MW et al (2010a) Mucopolysaccharidosis type IIID: 12 new patients and 15 novel mutations. Hum Mutat 31:E1348–E1360PubMed

Valstar MJ, Bruggenwirth HT, Olmer R et al (2010b) Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype. J Inherit Metab Dis 33:759–767PubMedCrossRef

Valstar MJ, Neijs S, Bruggenwirth HT et al (2010c) Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations. Ann Neurol 68:876–887PubMedCrossRef

van de Kamp JJ, von Niermeijer MFFK, Giesberts MA (1981) Genetic heterogeneity and clinical variability in the Sanfilippo syndrome (types A, B, and C). Clin Genet 20:152–160PubMedCrossRef

Weber B, Guo XH, Kleijer WJ, van de Kamp JJ, Poorthuis BJ, Hopwood JJ (1999) Sanfilippo type B syndrome (mucopolysaccharidosis III B): allelic heterogeneity corresponds to the wide spectrum of clinical phenotypes. Eur J Hum Genet 7:34–44PubMedCrossRef

Wegrzyn A (2012) Gene expression-targeted isoflavone therapy. IUBMB Life 64:307–315PubMedCrossRef

Wraith JE (2005) The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother 6:489–506PubMedCrossRef

Wraith JE, Clarke LA, Beck M et al (2004) Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 144:581–588PubMedCrossRef

Yogalingam G, Hopwood JJ (2001) Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications. Hum Mutat 18:264–281PubMedCrossRef

Titel: Heparan sulfate derived disaccharides in plasma and total urinary excretion of glycosaminoglycans correlate with disease severity in Sanfilippo disease
verfasst von: J. de Ruijter
L. IJlst
W. Kulik
H. van Lenthe
T. Wagemans
N. van Vlies
F. A. Wijburg
Publikationsdatum: 01.03.2013
Verlag: Springer Netherlands
Erschienen in: Journal of Inherited Metabolic Disease / Ausgabe 2/2013
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI: https://doi.org/10.1007/s10545-012-9535-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

Mucopolysaccharidoses (MPS)

Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA

Management of mucopolysaccharidosis type IH (Hurler’s syndrome) presenting in infancy with severe dilated cardiomyopathy: a single institution’s experience

Molecular characterization of 355 mucopolysaccharidosis patients reveals 104 novel mutations

Endothelial function in children and adolescents with mucopolysaccharidosis

Respiratory and sleep disorders in mucopolysaccharidosis